Why Ford Shares Are Moving During Monday’s After-Hours Session

Ford Motor Company (NYSE: F) shares are trading lower by 4.55% to $14.24 during Monday's after-hours session. Ford previewed the effect of parts shortages on the company in the third-quarter and reaffirmed full-year adjusted EBIT guidance as low as $11.5 billion or as high as $12.5 billion.

Ford Motor Company (NYSE:F) shares are trading lower by 4.55% to $14.24 during Monday’s after-hours session. Ford previewed the effect of parts shortages on the company in the third-quarter and reaffirmed full-year adjusted EBIT guidance as low as $11.5 billion or as high as $12.5 billion.

What Happened?

Ford says the company Expects to have about 40,000 to 45,000 vehicles in inventory at end of third quarter lacking certain parts presently in short supply

  • Ford says “vehicles on wheels” awaiting those parts disproportionately include high-demand, high-margin models of popular trucks and SUVs
  • The company notes that completing such vehicles will shift some revenue and EBIT to fourth-quarter; based on recent negotiations, inflation-related third-quarter supply costs will be ~$1.0 billion above plan
  • Anticipates third-quarter adjusted EBIT of between $1.4 billion and $1.7 billion

 

According to Ford, based on recent negotiations, inflation-related supplier costs during the third quarter will run about $1.0 billion higher than originally expected. Ford now anticipates third-quarter adjusted EBIT to be in the range of $1.4 billion and $1.7 billion.

The company intends to announce full third-quarter 2022 financial results – and provide more dimension about expectations for full-year performance – on Wednesday, October 26th.

See Also: Why Purple Innovation Shares Are Skyrocketing 50% Higher Monday

According to data from Benzinga Pro, Ford has a 52-week high of $25.87 and a 52-week low of $10.61.

Total
0
Shares
Related Posts
Read More

Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults with desmoid tumors. SpringWorks Therapeutics shares rose 14.4% to $23.77 in pre-market trading

ALYA